Non muscle invasive bladder cancer (NMIBC) refers to a type of bladder cancer confined to the inner lining surface of the bladder without penetrating the bladder muscle wall. NMIBC comprises 70-80% of newly diagnosed bladder cancers. It is treated primarily through transurethral resection of bladder tumor which aims at removing all visible tumors. However, the cancer has a very high recurrence rate, with 50-70% of cases recurring within 5 years of initial diagnosis. Regular checkups and testing of urine cytology is required to monitor recurrence. NMIBC poses a significant psychological and economic burden on patients, healthcare systems and society.
The global non muscle invasive bladder cancer market is estimated to be valued at US$ 342 Mn in 2024 and is expected to exhibit a CAGR of 8.3% over the forecast period 2024-2031.
Key Takeaways
Key players operating in the non muscle invasive bladder cancer market are Merck & Co., Inc.,Ferring Pharmaceuticals,Pfizer Inc.,CG Oncology,Sesen Bio, Inc. NMIBC recurrence rates continues to drive the demand for effective therapeutic options in the market. Several market players are investing in research and development of novel drugs and combination therapies to reduce recurrence rates. The non muscle invasive bladder cancer market is also witnessing increased expansion in regions such as Asia Pacific and Latin America owing to growing prevalence of bladder cancer and improved access to diagnostics and treatment.
Market key trends
One of the key trends witnessed in the non muscle invasive bladder cancer market is the increased focus on immunotherapy. Immune checkpoint inhibitors that help boost the body’s own immune response against cancer cells are being evaluated for NMIBC. Companies are conducting clinical trials to evaluate immunotherapies such as pembrolizumab, atezolizumab and BCG immunotherapy combinations to boost efficacy and reduce recurrence rates in high risk NMIBC. This novel approach holds potential to change the treatment landscape of non muscle invasive bladder cancer in the coming years.
Porter’s Analysis
Threat of new entrants: High costs of R&D, clinical trials, and regulatory approvals for new drugs pose barriers to entry.
Bargaining power of buyers: Large customer base of patients with non-muscle invasive bladder cancer creates less buyer power for individual customers.
Bargaining power of suppliers: Presence of several pharmaceutical companies developing drugs for non-muscle invasive bladder cancer indicates moderate supplier power.
Threat of new substitutes: Limited substitute treatment options available for bladder cancer provides less threat from new substitutes.
Competitive rivalry: Significant research investments made by large pharmaceutical companies to develop novel drugs results in high competition.
Geographical Regions
North America currently leads the global non-muscle invasive bladder cancer market in terms of value, owing to high healthcare expenditures and growing cancer incidence in the U.S. and Canada.
The Asia Pacific region is poised to witness the fastest growth over the forecast period due to rising healthcare standards, growing disposable incomes, and increasing accessibility to advanced treatment options in China, India, and other developing countries.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it